Abstract
Medicinal combinations of Isaria japonica (Paecilomyces tenuipes, Paecilomyces japonica, and Isaria tenuipes) and the silkworm Bombyx mori are commercially available in Japan, China, and Korea. Isaria japonica exhibits host specificity for lepidopteran insects and can be cultured in the insect’s body. Recently, a hot-water extract of an I. japonica product (“IJE”) was shown to prevent brain function decline in aging mice. Therefore, evaluating the safety profile of IJE is worthwhile. Acute toxicity experiments were performed on adult female ICR mice (8-10 weeks old; 25-35 g). Sub-chronic toxicity experiments on adult female Wistar rats (8-10 weeks old; 130-150 g) assessed general behavior, mortality, body weight, food + water consumption, hematology, blood chemistry, relative organ weights and histopathology. IJE caused neither significant visible signs of toxicity nor mortality in ICR mice. In the sub-chronic toxicity analysis, administration of IJE to Wistar rats at doses of 25 and 500 mg/kg for 28 consecutive days did not cause mortality. No significant differences were found in food or water consumption, hematological parameters, or relative organ weights between the treated and control groups. IJE appears to be safe when administered orally.
Keywords: Acute toxicity, Animals, Biochemical parameters, Hot-water extract, Isaria japonica, subchronic toxicity.
Current Traditional Medicine
Title:Acute and Sub-chronic Toxicity Analyses of Hot-Water Extract of Isaria japonica from Silkworm (Bombyx mori) Pupae
Volume: 1 Issue: 3
Author(s): Piyamas Sillapakong, Masanobu Goryo, Jun Sasaki, Shinichi Oda, Takashi Hiraga, Shorta Uchiyama, Eiji Nishimura, Tetsuro Shinada, Chigumi Ohtsuka, Yasuo Terayama and Koichi Suzuki
Affiliation:
Keywords: Acute toxicity, Animals, Biochemical parameters, Hot-water extract, Isaria japonica, subchronic toxicity.
Abstract: Medicinal combinations of Isaria japonica (Paecilomyces tenuipes, Paecilomyces japonica, and Isaria tenuipes) and the silkworm Bombyx mori are commercially available in Japan, China, and Korea. Isaria japonica exhibits host specificity for lepidopteran insects and can be cultured in the insect’s body. Recently, a hot-water extract of an I. japonica product (“IJE”) was shown to prevent brain function decline in aging mice. Therefore, evaluating the safety profile of IJE is worthwhile. Acute toxicity experiments were performed on adult female ICR mice (8-10 weeks old; 25-35 g). Sub-chronic toxicity experiments on adult female Wistar rats (8-10 weeks old; 130-150 g) assessed general behavior, mortality, body weight, food + water consumption, hematology, blood chemistry, relative organ weights and histopathology. IJE caused neither significant visible signs of toxicity nor mortality in ICR mice. In the sub-chronic toxicity analysis, administration of IJE to Wistar rats at doses of 25 and 500 mg/kg for 28 consecutive days did not cause mortality. No significant differences were found in food or water consumption, hematological parameters, or relative organ weights between the treated and control groups. IJE appears to be safe when administered orally.
Export Options
About this article
Cite this article as:
Sillapakong Piyamas, Goryo Masanobu, Sasaki Jun, Oda Shinichi, Hiraga Takashi, Uchiyama Shorta, Nishimura Eiji, Shinada Tetsuro, Ohtsuka Chigumi, Terayama Yasuo and Suzuki Koichi, Acute and Sub-chronic Toxicity Analyses of Hot-Water Extract of Isaria japonica from Silkworm (Bombyx mori) Pupae, Current Traditional Medicine 2015; 1 (3) . https://dx.doi.org/10.2174/221508380103151231145946
DOI https://dx.doi.org/10.2174/221508380103151231145946 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
Anti-Cancer Agents in Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Biodegradable Nanoparticles: A Recent Approach and Applications
Current Drug Targets Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Antimicrobial Activity of Phenolics and Glucosinolate Hydrolysis Products and their Synergy with Streptomycin against Pathogenic Bacteria
Medicinal Chemistry Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets The Effect of Casein Kinase 2 Inhibition on three Leukemic Cell Lines
Current Drug Therapy Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Isoenzyme Selective Phosphoinositide 3-Kinase Inhibition: What do the Stones Kill?
Current Signal Transduction Therapy Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Synthetic Approaches to Functionalized Lipids for Protein Monolayer Crystallizations
Current Organic Chemistry The Dark Side of Stem Cells: Triggering Cancer Progression by Cell Fusion
Current Molecular Medicine Targeting BCR-ABL Oncoprotein for Leukemia Therapy: Current Biotechnology and Future Perspectives
Current Biotechnology Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design